RECURSION PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
Pre-market 09:06:57 am | |||
| 7.94 USD | +3.18% |
|
7.78 | -2.02% |
| Apr. 18 | Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing | MT |
| Apr. 16 | Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer | MT |
Financials (USD)
| Sales 2024 * | 53.92M | Sales 2025 * | 60.67M | Capitalization | 1.89B |
|---|---|---|---|---|---|
| Net income 2024 * | -411M | Net income 2025 * | -481M | EV / Sales 2024 * | 29.1 x |
| Net cash position 2024 * | 322M | Net cash position 2025 * | 279M | EV / Sales 2025 * | 26.6 x |
| P/E ratio 2024 * |
-4.67
x | P/E ratio 2025 * |
-4.23
x | Employees | 500 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.33% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +3.18% | ||
| 1 week | +6.29% | ||
| Current month | -20.36% | ||
| 1 month | -24.31% | ||
| 3 months | -23.36% | ||
| 6 months | +31.02% | ||
| Current year | -19.47% |
1 week
7.14
8.27
1 month
7.1410.89
Current year
7.1415.74
1 year
4.5416.75
3 years
4.5442.81
5 years
4.5442.81
10 years
4.5442.81
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 41 | 13-11-04 | |
Blake Borgeson
FOU | Founder | 42 | 13-11-04 |
Dean Li
FOU | Founder | 62 | 13-11-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 20-03-19 |
| Chairman | 60 | 20-03-31 | |
Dean Li
FOU | Founder | 62 | 13-11-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.51% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 7.94 | +3.12% | 7,206,016 |
| 24-04-23 | 7.7 | +1.32% | 5,111,318 |
| 24-04-22 | 7.6 | +3.40% | 3,946,342 |
| 24-04-19 | 7.35 | -0.68% | 4,013,543 |
| 24-04-18 | 7.4 | -0.94% | 2,862,410 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
7.94
USD
Average target price
13
USD
Spread / Average Target
+63.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.47% | 1.89B | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +0.52% | 22.2B | |
| -16.53% | 21.23B | |
| -8.45% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- RXRX Stock
